Abstract
This paper reviews high-resolution mass spectrometry (HRMS) approaches using time-of-flight or Orbitrap techniques for research and application in various toxicology fields, particularly in clinical toxicology and forensic toxicology published since 2013 and referenced in PubMed. In the introduction, an overview on applications of HRMS in various toxicology fields is given with reference to current review articles. Papers concerning HRMS in metabolism, screening, and quantification of pharmaceuticals, drugs of abuse, and toxins in human body samples are critically reviewed. Finally, a discussion on advantages as well as limitations and future perspectives of these methods is included.
Similar content being viewed by others
References
Acena J, Stampachiacchiere S, Perez S, Barcelo D (2015) Advances in liquid chromatography-high-resolution mass spectrometry for quantitative and qualitative environmental analysis. Anal Bioanal Chem 407:6289–6299
Andersson M, Diao X, Wohlfarth A, Scheidweiler KB, Huestis MA (2016) Metabolic profiling of new synthetic cannabinoids AMB and 5F-AMB by human hepatocyte and liver microsome incubations and high-resolution mass spectrometry. Rapid Commun Mass Spectrom 30:1067–1078
Anizan S, Concheiro M, Lehner KR, Bukhari MO, Suzuki M, Rice KC, Baumann MH, Huestis MA (2016) Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects. Addict Biol 21:339–347
Arnhard K, Gottschall A, Pitterl F, Oberacher H (2015) Applying ‘Sequential Windowed Acquisition of All Theoretical Fragment Ion Mass Spectra’ (SWATH) for systematic toxicological analysis with liquid chromatography-high-resolution tandem mass spectrometry. Anal Bioanal Chem 407:405–414
Bale SS, Moore L, Yarmush M, Jindal R (2016) Emerging in vitro liver technologies for drug metabolism and inter-organ interactions. Tissue Eng Part B Rev. doi:10.1089/ten.teb.2016.0031
Beck O, Ericsson M (2014) Methods for urine drug testing using one-step dilution and direct injection in combination with LC–MS/MS and LC–HRMS. Bioanalysis 6:2229–2244
Carlier J, Romeuf L, Guitton J, Priez-Barallon C, Bevalot F, Fanton L, Gaillard Y (2014) A validated method for quantifying atractyloside and carboxyatractyloside in blood by HPLC–HRMS/MS, a non-fatal case of intoxication with Atractylis gummifera L. J Anal Toxicol 38:619–627
Caspar AT, Helfer AG, Michely JA, Auwaerter V, Brandt SD, Meyer MR, Maurer HH (2015) Studies on the metabolism and toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in human and rat urine using GC–MS, LC–MSn, and LC–HR-MS/MS. Anal Bioanal Chem 407:6697–6719
Castaneto MS, Wohlfarth A, Desrosiers NA, Hartman RL, Gorelick DA, Huestis MA (2015) Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices. Drug Metab Rev 47:124–174
Cece-Esencan EN, Fontaine F, Plasencia G, Teppner M, Brink A, Pahler A, Zamora I (2016) Software-aided cytochrome P450 reaction phenotyping and kinetic analysis in early drug discovery. Rapid Commun Mass Spectrom 30:301–310
Chindarkar NS, Wakefield MR, Stone JA, Fitzgerald RL (2014) Liquid chromatography high-resolution TOF analysis: investigation of MSE for broad-spectrum drug screening. Clin Chem 60:1115–1125
Chowdhury R, Khan H, Heydon E et al (2013) Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 34:2940–2948
Concheiro M, Anizan S, Ellefsen K, Huestis MA (2013) Simultaneous quantification of 28 synthetic cathinones and metabolites in urine by liquid chromatography-high resolution mass spectrometry. Anal Bioanal Chem 405:9437–9448
Concheiro M, Castaneto M, Kronstrand R, Huestis MA (2015) Simultaneous determination of 40 novel psychoactive stimulants in urine by liquid chromatography-high resolution mass spectrometry and library matching. J Chromatogr A 1397:32–42
Dalsgaard PW, Rode AJ, Pedersen AJ, Rasmussen BS, Windberg CN, Linnet K (2013) Screening of 30 acidic and neutral pharmaceuticals in whole blood by fully automated SPE and UPLC–TOF–MS(E.). Drug Test Anal 5:254–258
Diao X, Scheidweiler KB, Wohlfarth A, Pang S, Kronstrand R, Huestis MA (2016a) In vitro and in vivo human metabolism of synthetic cannabinoids FDU-PB-22 and FUB-PB-22. AAPS J 18:455–464
Diao X, Wohlfarth A, Pang S, Scheidweiler KB, Huestis MA (2016b) High-resolution mass spectrometry for characterizing the metabolism of synthetic cannabinoid THJ-018 and Its 5-fluoro analog THJ-2201 after incubation in human hepatocytes. Clin Chem 62:157–169
Dinger J, Meyer MR, Maurer HH (2014a) Development and validation of a liquid-chromatography high-resolution tandem mass spectrometry approach for quantification of nine cytochrome P450 (CYP) model substrate metabolites in an in vitro CYP inhibition cocktail. Anal Bioanal Chem 406:4453–4464
Dinger J, Meyer MR, Maurer HH (2014b) Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse. Toxicol Lett 230:28–35
Dinger J, Meyer MR, Maurer HH (2016a) In vitro cytochrome P450 inhibition potential of methylenedioxy-derived designer drugs studied with a two cocktail approach. Arch Toxicol 90:305–318
Dinger J, Woods C, Brandt SD, Meyer MR, Maurer HH (2016b) Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett 241:82–94
Dupre M, Gilquin B, Fenaille F et al (2015) Multiplex quantification of protein toxins in human biofluids and food matrices using immunoextraction and high-resolution targeted mass spectrometry. Anal Chem 87:8473–8480
Ellefsen KN, Wohlfarth A, Swortwood MJ, Diao X, Concheiro M, Huestis MA (2016) 4-Methoxy-alpha-PVP: in silico prediction, metabolic stability, and metabolite identification by human hepatocyte incubation and high-resolution mass spectrometry. Forensic Toxicol 34:61–75
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2015) European drug report: trends and developments. http://www.emcdda.europa.eu/attachements.cfm/att_239505_EN_TDAT15001ENN.pdf
Ewald AH, Peters FT, Weise M, Maurer HH (2005) Studies on the metabolism and toxicological detection of the designer drug 4-methylthioamphetamine (4-MTA) in human urine using gas chromatography-mass spectrometry. J Chromatogr B 824:123–131
Ewen S, Meyer MR, Cremers B et al (2015) Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. Clin Res Cardiol 104:1097–1105
Farrell EK, Merkler DJ (2008) Biosynthesis, degradation and pharmacological importance of the fatty acid amides. Drug Discov Today 13:558–568
Favretto D, Stocchero G, Nalesso A, Vogliardi S, Boscolo-Berto R, Montisci M, Ferrara SD (2013) Monitoring haloperidol exposure in body fluids and hair of children by liquid chromatography-high-resolution mass spectrometry. Ther Drug Monit 35:493–501
Gandhi AS, Zhu M, Pang S, Wohlfarth A, Scheidweiler KB, Liu HF, Huestis MA (2013) First characterization of AKB-48 metabolism, a novel synthetic cannabinoid, using human hepatocytes and high-resolution mass spectrometry. AAPS J 15:1091–1098
Gandhi AS, Zhu M, Pang S, Wohlfarth A, Scheidweiler KB, Huestis MA (2014) Metabolite profiling of RCS-4, a novel synthetic cannabinoid designer drug, using human hepatocyte metabolism and TOF–MS. Bioanalysis 6:1471–1485
Gandhi AS, Wohlfarth A, Zhu M, Pang S, Castaneto M, Scheidweiler KB, Huestis MA (2015) High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liver microsomes. Drug Test Anal 7:187–198
Gicquel T, Lepage S, Fradin M, Tribut O, Duretz B, Morel I (2014) Amatoxins (alpha- and beta-Amanitin) and phallotoxin (Phalloidin) analyses in urines using high-resolution accurate mass LC–MS technology. J Anal Toxicol 38:335–340
Godoy P, Hewitt NJ, Albrecht U et al (2013) Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 87:1315–1530
Gous T, Couchman L, Patel JP, Paradzai C, Arya R, Flanagan RJ (2014) Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry. Ther Drug Monit 36:597–605
Guale F, Shahreza S, Walterscheid JP, Chen HH, Arndt C, Kelly AT, Mozayani A (2013) Validation of LC–TOF–MS screening for drugs, metabolites, and collateral compounds in forensic toxicology specimens. J Anal Toxicol 37:17–24
Helfer AG, Meyer MR, Michely JA, Maurer HH (2014) Direct analysis of the mushroom poisons alpha- and beta-amanitin in human urine using a novel on-line turbulent flow chromatography mode coupled to LC-high resolution-MS/MS. J Chromatogr A 1325:92–98
Helfer AG, Michely JA, Weber AA, Meyer MR, Maurer HH (2015a) Orbitrap technology for comprehensive metabolite-based liquid chromatographic-high resolution-tandem mass spectrometric urine drug screening—exemplified for cardiovascular drugs. Anal Chim Acta 891:221–233
Helfer AG, Turcant A, Boels D, Ferec S, Lelievre B, Welter J, Meyer MR, Maurer HH (2015b) Elucidation of the metabolites of the novel psychoactive substance 4-methyl-N-ethyl-cathinone (4-MEC) in human urine and pooled liver microsomes by GC–MS and LC–HR-MS/MS techniques and of its detectability by GC–MS or LC–MSn standard screening approaches. Drug Test Anal 7:368–375
Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW (2013) Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 31:766–774
Kinyua J, Negreira N, Ibanez M, Bijlsma L, Hernandez F, Covaci A, van Nuijs AL (2015) A data-independent acquisition workflow for qualitative screening of new psychoactive substances in biological samples. Anal Bioanal Chem 407:8773–8785
Knolhoff AM, Croley TR (2016) Non-targeted screening approaches for contaminants and adulterants in food using liquid chromatography hyphenated to high resolution mass spectrometry. J Chromatogr A 1428:86–96
Kronstrand R, Brinkhagen L, Birath-Karlsson C, Roman M, Josefsson M (2014) LC-QTOF-MS as a superior strategy to immunoassay for the comprehensive analysis of synthetic cannabinoids in urine. Anal Bioanal Chem 406:3599–3609
Lai FY, Erratico C, Kinyua J, Mueller JF, Covaci A, van Nuijs AL (2015) Liquid chromatography-quadrupole time-of-flight mass spectrometry for screening in vitro drug metabolites in humans: investigation on seven phenethylamine-based designer drugs. J Pharm Biomed Anal 114:355–375
Lawson G, Cocks E, Tanna S (2013) Bisoprolol, ramipril and simvastatin determination in dried blood spot samples using LC–HRMS for assessing medication adherence. J Pharm Biomed Anal 81–82:99–107
Lawson AJ, Shipman KE, George S, Dasgupta I (2016) A novel ‘Dilute-and-Shoot’ liquid chromatography-tandem mass spectrometry method for the screening of antihypertensive drugs in urine. J Anal Toxicol 40:17–27
Lesur A, Domon B (2015) Advances in high-resolution accurate mass spectrometry application to targeted proteomics. Proteomics 15:880–890
Li X, Shen B, Jiang Z, Huang Y, Zhuo X (2013) Rapid screening of drugs of abuse in human urine by high-performance liquid chromatography coupled with high resolution and high mass accuracy hybrid linear ion trap-Orbitrap mass spectrometry. J Chromatogr A 1302:95–104
Linicus Y, Kindermann I, Helfer AG, Meyer MR, Maurer HH, Mahfound F, Böhm M (2015) Witnessed drug intake before planned denervation-always harmless? Int J Cardiol 179:125–126
Lung D, Wilson N, Chatenet FT, Lacroix C, Gerona R (2016) Non-targeted screening for novel psychoactive substances among agitated emergency department patients. Clin Toxicol (Phila) 54:319–323
Ma S, Chowdhury SK (2013) Data acquisition and data mining techniques for metabolite identification using LC coupled to high-resolution MS. Bioanalysis 5:1285–1297
Mardal M, Meyer MR (2014) Studies on the microbial biotransformation of the novel psychoactive substance methylenedioxypyrovalerone (MDPV) in wastewater by means of liquid chromatography-high resolution mass spectrometry/mass spectrometry. Sci Total Environ 493:588–595
Mardal M, Gracia-Lor E, Leibnitz S, Castiglioni S, Meyer MR (2016) Toxicokinetics of new psychoactive substances: plasma protein binding, metabolic stability, and human phase I metabolism of the synthetic cannabinoid WIN 55,212-2 studied using in vitro tools and LC-HR-MS/MS. Drug Test Anal. doi:10.1002/dta.1938
Marin SJ, Sawyer JC, He X, Johnson-Davis KL (2015) Comparison of drug detection by three quadrupole time-of-flight mass spectrometry platforms. J Anal Toxicol 39:89–95
Marzinke MA, Breaud A, Parsons TL, Cohen MS, Piwowar-Manning E, Eshleman SH, Clarke W (2014) The development and validation of a method using high-resolution mass spectrometry (HRMS) for the qualitative detection of antiretroviral agents in human blood. Clin Chim Acta 433:157–168
Maurer HH (1996) On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry. Ther Drug Monit 18:465–470
Maurer HH (2007) Demands on scientific studies in clinical toxicology [review]. Forensic Sci Int 165:194–198
Maurer HH, Schmitt CJ, Weber AA, Kraemer T (2000) Validated electrospray LC–MS assay for determination of the mushroom toxins alpha- and beta-amanitin in urine after immunoaffinity extraction. J Chromatogr B 748:125–135
McCall AK, Bade R, Kinyua J, Lai FY, Thai PK, Covaci A, Bijlsma L, van Nuijs AL, Ort C (2016) Critical review on the stability of illicit drugs in sewers and wastewater samples. Water Res 88:933–947
McMillin GA, Marin SJ, Johnson-Davis KL, Lawlor BG, Strathmann FG (2015) A hybrid approach to urine drug testing using high-resolution mass spectrometry and select immunoassays. Am J Clin Pathol 143:234–240
Meyer MR (2016) New psychoactive substances: toxicokinetics and toxicodynamics. Arch Toxicol (submitted)
Meyer MR, Maurer HH (2012a) Current applications of high-resolution mass spectrometry in drug metabolism studies [review]. Anal Bioanal Chem 403:1221–1231
Meyer MR, Maurer HH (2012b) Current status of hyphenated mass spectrometry in studies of the metabolism of drugs of abuse, including doping agents [review]. Anal Bioanal Chem 402:195–208
Meyer GMJ, Maurer HH (2013) Qualitative metabolism assessment and toxicological detection of xylazine, a veterinary tranquilizer and drug of abuse, in rat and human urine using GC–MS, LC–MSn, and LC–HR-MSn. Anal Bioanal Chem 405:9779–9789
Meyer MR, Maurer HH (2016) Review: LC coupled to low- and high-resolution mass spectrometry for new psychoactive substance screening in biological matrices—where do we stand today? Anal Chim Acta 927:12–20
Meyer GMJ, Meyer MR, Wink CSD, Zapp J, Maurer HH (2013a) Studies on the in vivo contribution of human cytochrome P450s to the hepatic metabolism of glaucine, a new drug of abuse. Biochem Pharmacol 86:1497–1506
Meyer GMJ, Meyer MR, Wissenbach DK, Maurer HH (2013b) Studies on the metabolism and toxicological detection of glaucine, an isoquinoline alkaloid from Glaucium flavum (Papaveraceae), in rat urine using GC–MS, LC–MSn and LC–high-resolution MSn. J Mass Spectrom 48:24–41
Meyer MR, Bach M, Welter J, Bovens M, Turcant A, Maurer HH (2013c) Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC–MS and LC–(HR-)MSn. Anal Bioanal Chem 405:6307–6321
Meyer MR, Posser D, Maurer HH (2013d) Studies on the metabolism and detectability of the designer drug â-naphyrone in rat urine using GC–MS and LC–HR-MS/MS. Drug Test Anal 5:259–265
Meyer MR, Schmitt S, Maurer HH (2013e) Studies on the metabolism and detectability of the emerging drug of abuse diphenyl-2-pyrrolidinemethanol (D2PM) in rat urine using GC–MS and LC–HR-MS/MS. J Mass Spectrom 48:243–249
Meyer MR, Helfer AG, Maurer HH (2014a) Current position of high-resolution mass spectrometry for drug quantification in clinical & forensic toxicology [review]. Bioanalysis 6:2275–2284
Meyer MR, Lindauer C, Maurer HH (2014b) Dimethocaine, a synthetic cocaine derivative: studies on its in vitro metabolism catalyzed by P450s and NAT2. Toxicol Lett 225:139–146
Meyer MR, Lindauer C, Welter J, Maurer HH (2014c) Dimethocaine, a synthetic cocaine derivative: studies on its in vivo metabolism and its detectability in urine by LC–HR-MSn and GC–MS using a rat model. Anal Bioanal Chem 406:1845–1854
Meyer MR, Mauer S, Meyer GMJ, Dinger J, Klein B, Westphal F, Maurer HH (2014d) The in vivo and in vitro metabolism and the detectability in urine of 3′,4′-methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP), a new pyrrolidinophenone-type designer drug, studied by GC–MS and LC–MSn. Drug Test Anal 6:746–756
Meyer MR, Robert A, Maurer HH (2014e) Toxicokinetics of novel psychoactive substances: characterization of N-acetyltransferase (NAT) isoenzymes involved in the phase II metabolism of 2C designer drugs. Toxicol Lett 227:124–128
Meyer MR, Schütz A, Maurer HH (2014f) Contribution of human esterases to the metabolism of selected drugs of abuse. Toxicol Lett 232:159–166
Meyer MR, Holderbaum A, Kavanagh P, Maurer HH (2015) Low and high resolution MS for studies on the metabolism and toxicological detection of the new psychoactive substance methoxypiperamide (MeOP). J Mass Spectrom 50:1163–1174
Meyer GM, Maurer HH, Meyer MR (2016) Multiple stage MS in analysis of plasma, serum, urine and in vitro samples relevant to clinical and forensic toxicology. Bioanalysis. doi:10.4155/bio.16.15
Michely JA, Helfer AG, Brandt SD, Meyer MR, Maurer HH (2015) Metabolism of the new psychoactive substances N, N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC–MS, LC–MSn, and LC–HR-MS/MS. Anal Bioanal Chem 407:7831–7842
Ojanpera I, Mesihaa S, Rasanen I, Pelander A, Ketola RA (2016) Simultaneous identification and quantification of new psychoactive substances in blood by GC-APCI-QTOFMS coupled to nitrogen chemiluminescence detection without authentic reference standards. Anal Bioanal Chem 408:3395–3400
Pasin D, Bidny S, Fu S (2015) Analysis of new designer drugs in post-mortem blood using high-resolution mass spectrometry. J Anal Toxicol 39:163–171
Patteet L, Cappelle D, Maudens KE, Crunelle CL, Sabbe B, Neels H (2015) Advances in detection of antipsychotics in biological matrices. Clin Chim Acta 441C:11–22
Pedersen AJ, Dalsgaard PW, Rode AJ, Rasmussen BS, Muller IB, Johansen SS, Linnet K (2013) Screening for illicit and medicinal drugs in whole blood using fully automated SPE and ultra-high-performance liquid chromatography with TOF-MS with data-independent acquisition. J Sep Sci 36:2081–2089
Peters FT (2014) Recent developments in urinalysis of metabolites of new psychoactive substances using LC-MS. Bioanalysis 6:2083–2107
Peters FT, Meyer MR (2011) In vitro approaches to studying the metabolism of new psychoactive compounds [review]. Drug Test Anal 3:483–495
Peters FT, Dragan CA, Kauffels A, Schwaninger AE, Zapp J, Bureik M, Maurer HH (2009) Biotechnological synthesis of the designer drug metabolite 4′-hydroxymethyl-alpha-pyrrolidinohexanophenone in fission yeast heterologously expressing human cytochrome P450 2D6—a versatile alternative to multistep chemical synthesis. J Anal Toxicol 33:190–197
Rejczak T, Tuzimski T (2015) Recent trends in sample preparation and liquid chromatography/mass spectrometry for pesticide residue analysis in food and related matrixes. J AOAC Int 98:1143–1162
Richter LHR, Kaminski YR, Noor F, Meyer MR, Maurer HH (2016) Metabolic fate of desomorphine elucidated using rat urine, pooled human liver preparations, and human hepatocyte cultures as well as its detectability using standard urine screening approaches. Anal Bioanal Chem. doi:10.1007/s00216-016-9740-4
Roche L, Pinguet J, Herviou P, Libert F, Chenaf C, Eschalier A, Authier N, Richard D (2016) Fully automated semi-quantitative toxicological screening in three biological matrices using turbulent flow chromatography/high resolution mass spectrometry. Clin Chim Acta 455:46–54
Roemmelt AT, Steuer AE, Poetzsch M, Kraemer T (2014) Liquid chromatography, in combination with a quadrupole time-of-flight instrument (LC QTOF), with sequential window acquisition of all theoretical fragment-ion spectra (SWATH) acquisition: systematic studies on its use for screenings in clinical and forensic toxicology and comparison with information-dependent acquisition (IDA). Anal Chem 86:11742–11749
Roemmelt AT, Steuer AE, Kraemer T (2015) Liquid chromatography, in combination with a quadrupole time-of-flight instrument, with sequential window acquisition of all theoretical fragment-ion spectra acquisition: validated quantification of 39 antidepressants in whole blood as part of a simultaneous screening and quantification procedure. Anal Chem 87:9294–9301
Sajic T, Liu Y, Aebersold R (2015) Using data-independent, high-resolution mass spectrometry in protein biomarker research: perspectives and clinical applications. Proteomics Clin Appl 9:307–321
Schaefer N, Helfer AG, Kettner M et al (2016) Metabolic patterns of JWH-210, RCS-4, and THC in pig urine elucidated using LC–HR-MS/MS—do they reflect patterns in humans? Drug Test Anal. doi:10.1002/dta.1995
Schanzer W, Thevis M (2015) Human sports drug testing by mass spectrometry. Mass Spectrom Rev. doi:10.1002/mas.21479
Scheidweiler KB, Jarvis MJ, Huestis MA (2015) Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry. Anal Bioanal Chem 407:883–897
Schmieder RE, Ott C, Schmid A, Friedrich S, Kistner I, Ditting T, Veelken R, Uder M, Toennes SW (2016) Adherence to antihypertensive medication in treatment-resistant hypertension undergoing renal denervation. J Am Heart Assoc 5:e002343. doi:10.1161/JAHA.115.002343
Schneider KJ, DeCaprio AP (2013) Covalent thiol adducts arising from reactive intermediates of cocaine biotransformation. Chem Res Toxicol 26:1755–1764
Schwaninger AE, Meyer MR, Huestis MA, Maurer HH (2011) Development and validation of LC-HRMS and GC-NICI-MS methods for stereoselective determination of methylenedioxymethamphetamine (MDMA) and its phase I and II metabolites in human urine. J Mass Spectrom 46:603–614
Senyuva HZ, Gokmen V, Sarikaya EA (2015) Future perspectives in orbitrap-high-resolution mass spectrometry in food analysis: a review. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 32:1568–1606
Staack RF, Fehn J, Maurer HH (2003) New designer drug para-methoxymethamphetamine: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. J Chromatogr B 789:27–41
Staack RF, Theobald DS, Paul LD, Springer D, Kraemer T, Maurer HH (2004) Identification of human cytochrome p450 2D6 as major enzyme involved in the o-demethylation of the designer drug p-methoxymethamphetamine. Drug Metab Dispos 32:379–381
Sundstrom M, Pelander A, Angerer V, Hutter M, Kneisel S, Ojanpera I (2013) A high-sensitivity ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry (UHPLC–HR-TOFMS) method for screening synthetic cannabinoids and other drugs of abuse in urine. Anal Bioanal Chem 405:8463–8474
Swortwood MJ, Carlier J, Ellefsen KN, Wohlfarth A, Diao X, Concheiro-Guisan M, Kronstrand R, Huestis MA (2016) In vitro, in vivo and in silico metabolic profiling of alpha-pyrrolidinopentiothiophenone, a novel thiophene stimulant. Bioanalysis 8:65–82
Thevis M, Kuuranne T, Walpurgis K, Geyer H, Schanzer W (2016) Annual banned-substance review: analytical approaches in human sports drug testing. Drug Test Anal 8:7–29
Thoren KL, Colby JM, Shugarts SB, Wu AH, Lynch KL (2016) Comparison of information-dependent acquisition on a tandem quadrupole TOF vs a triple quadrupole linear ion trap mass spectrometer for broad-spectrum drug screening. Clin Chem 62:170–178
Tomkova J, Ondra P, Valka I (2015) Simultaneous determination of mushroom toxins alpha-amanitin, beta-amanitin and muscarine in human urine by solid-phase extraction and ultra-high-performance liquid chromatography coupled with ultra-high-resolution TOF mass spectrometry. Forensic Sci Int 251:209–213
Tsai IL, Weng TI, Tseng YJ, Tan HK, Sun HJ, Kuo CH (2013) Screening and confirmation of 62 drugs of abuse and metabolites in urine by ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry. J Anal Toxicol 37:642–651
United Nations Office on Drugs and Crime (UNODC) (2015) World drug report 2015. https://www.unodc.org/documents/wdr2015/World_Drug_Report_2015.pdf
van den Broek I, Blokland M, Nessen MA, Sterk S (2015) Current trends in mass spectrometry of peptides and proteins: application to veterinary and sports-doping control. Mass Spectrom Rev 34:571–594
Welter J, Meyer MR, Wolf E, Weinmann W, Kavanagh P, Maurer HH (2013) 2-Methiopropamine, a thiophene analogue of methamphetamine: studies on its metabolism and detectability in the rat and human using GC-MS and LC-(HR)-MS techniques. Anal Bioanal Chem 405:3125–3135
Welter J, Kavanagh P, Maurer HH (2014a) GC–MS and LC-(high-resolution)-MSn studies on the metabolic fate and detectability of camfetamine in rat urine. Anal Bioanal Chem 406:3815–3829
Welter J, Meyer MR, Kavanagh P, Maurer HH (2014b) Studies on the metabolism and the detectability of 4-methyl-amphetamine and its isomers 2-methyl-amphetamine and 3-methyl-amphetamine in rat urine using GC-MS and LC-(high-resolution)-MSn. Anal Bioanal Chem 406:1957–1974
Welter J, Brandt SD, Kavanagh P, Meyer MR, Maurer HH (2015a) Metabolic fate, mass spectral fragmentation, detectability, and differentiation in urine of the benzofuran designer drugs 6-APB and 6-MAPB in comparison to their 5-isomers using GC–MS and LC–(HR)–MS techniques. Anal Bioanal Chem 407:3457–3470
Welter J, Kavanagh P, Meyer MR, Maurer HH (2015b) Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC–MS and LC-(HR)-MSn techniques. Anal Bioanal Chem 407:1371–1388
Welter-Luedeke J, Maurer HH (2015) New psychoactive substances: chemistry, pharmacology, metabolism, and detectability of amphetamine derivatives with modified ring systems. Ther Drug Monit 38:4–11
Wen B, Zhu M (2015) Applications of mass spectrometry in drug metabolism: 50 years of progress. Drug Metab Rev 47:71–87
Wink CSD, Meyer GMJ, Wissenbach DK, Jacobsen-Bauer A, Meyer MR, Maurer HH (2014) Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): metabolism and detectability in rat urine using GC–MS, LC–MSn and LC-high resolution (HR)–MS/MS. Drug Test Anal 6:1038–1048
Wink CSD, Meyer GMJ, Meyer MR, Maurer HH (2015a) Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs—contribution of human cytochrome P450 isozymes to their main phase I metabolic steps. Toxicol Lett 238:39–44
Wink CSD, Meyer GMJ, Zapp J, Maurer HH (2015b) Lefetamine, a controlled drug and pharmaceutical lead of new designer drugs: synthesis, metabolism, and detectability in urine and human liver preparations using GC-MS, LC-MSn, and LC-high resolution–MS/MS. Anal Bioanal Chem 407:1545–1557
Wink CSD, Meyer MR, Braun T, Turcant A, Maurer HH (2015c) Biotransformation and detectability of the designer drug 2,5-dimethoxy-4-propylphenethylamine (2C-P) studied in urine by GC–MS, LC–MSn and LC-high resolution-MSn. Anal Bioanal Chem 407:831–843
Wink CSD, Michely JA, Jacobsen-Bauer A, Zapp J, Maurer HH (2016) Diphenidine, a new psychoactive substance: metabolic fate elucidated with rat urine and human liver preparations and detectability in urine using GC–MS, LC–MSn, and LC–HR-MSn. Drug Test Anal. doi:10.1002/dta.1946
Wohlfarth A, Pang S, Zhu M, Gandhi AS, Scheidweiler KB, Liu HF, Huestis MA (2013) First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. Clin Chem 59:1638–1648
Wohlfarth A, Gandhi AS, Pang S, Zhu M, Scheidweiler KB, Huestis MA (2014a) Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. Anal Bioanal Chem 406:1763–1780
Wohlfarth A, Pang S, Zhu M, Gandhi AS, Scheidweiler KB, Huestis MA (2014b) Metabolism of RCS-8, a synthetic cannabinoid with cyclohexyl structure, in human hepatocytes by high-resolution MS. Bioanalysis 6:1187–1200
Wohlfarth A, Castaneto MS, Zhu M, Pang S, Scheidweiler KB, Kronstrand R, Huestis MA (2015a) Pentylindole/pentylindazole synthetic cannabinoids and their 5-fluoro analogs produce different primary metabolites: metabolite profiling for AB-PINACA and 5F-AB-PINACA. AAPS J 17:660–677
Wohlfarth A, Scheidweiler KB, Pang S, Zhu M, Castaneto M, Kronstrand R, Huestis MA (2015b) Metabolic characterization of AH-7921, a synthetic opioid designer drug: in vitro metabolic stability assessment and metabolite identification, evaluation of in silico prediction, and in vivo confirmation. Drug Test Anal. doi:10.1002/dta.1856
Zaitsu K, Nakayama H, Yamanaka M et al (2015) High-resolution mass spectrometric determination of the synthetic cannabinoids MAM-2201, AM-2201, AM-2232, and their metabolites in postmortem plasma and urine by LC/Q-TOFMS. Int J Legal Med 129:1233–1245
Znaleziona J, Ginterova P, Petr J, Ondra P, Valka I, Sevcik J, Chrastina J, Maier V (2015) Determination and identification of synthetic cannabinoids and their metabolites in different matrices by modern analytical techniques—a review. Anal Chim Acta 874:11–25
Zollner A, Buchheit D, Meyer MR, Maurer HH, Peters FT, Bureik M (2010) Production of human phase 1 and 2 metabolites by whole-cell biotransformation with recombinant microbes. Bioanalysis 2:1277–1290
Acknowledgments
The authors would like to thank Andreas G. Helfer and Julian A. Michely for their suggestions.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Maurer, H.H., Meyer, M.R. High-resolution mass spectrometry in toxicology: current status and future perspectives. Arch Toxicol 90, 2161–2172 (2016). https://doi.org/10.1007/s00204-016-1764-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-016-1764-1